Are your patients aware of how serious shingles can be?

Shingles is well known to cause a painful rash, blisters and excruciating nerve pain that can last for months, or even years.1,3

But people with shingles are also at risk of potentially life-changing complications.1,2,4

Up to 1 in 5 shingles sufferers may go on to experience post-herpetic neuralgia, which may last for months, even years.3,5

Cardiovascular events

The risk of myocardial infarction (MI), stroke or transient ischaemic attack (TIA) may be increased after an episode of shingles.4,6-8

There may be an increased risk of MU in the first few weeks following shingles.6-8


Shingles may increase the risk of stroke in the following six months vs baseline.4

View full study design

Vision loss

Ophthalmic shingles can lead to loss of vision1,2

Facial scarring

Ophthalmic shingles can also lead to facial scarring1,2

1 in 3 people may develop shingles in their lifetime, and the risk of developing shingles and related complications increases over the age of 70.1,2

Vaccination is important for the prevention of shingles and its complications.5,10

ZOSTAVAX® [Zoster Vaccine Live (Oka/Merck)] is the only single-dose shingles vaccination funded on the National Immunisation Program (NIP) for eligible adults 70–79 years.10,11*

*NIP catch-up program for 71-79 year olds is time limited.11

ZOSTAVAX® is a live vaccine, check contraindications before prescribing.10

For adults aged 70-79 years.12

ZOSTAVAX® single-dose shingles vaccination, available on the NIP for eligible patients.10,11

  1. Visit Community Immunity for resources to support shingles vaccination in your practice.
  2. Use your practice software to identify eligible patients.
  3. Recall eligible patients with letters, phone calls and sms reminders.
  4. Recommend vaccination to eligible patients visiting for other reasons, like influenza vaccination.

Remember - Recommendation is critical to protect your eligible patients from shingles10,13

PBS Information: This product is listed on the National Immunisation Program (NIP). Refer to the NIP Schedule.

Before prescribing, please review Product Information available at Further information is available on request from Seqirus.

1. Harpaz R et al. MMRW 2008 Jun 6; 57(RR-5):1–30. 2. National Centre for Immunisation Research and Surveillance. Herpes Zoster Fact Sheet. Available at: [Accessed February 2019]. 3. Oxman MN et al. In: Arvin AM et al (EDs). Varicella-Zoster Virus: Virology and Clinical Management 2000: 246–75. 4. Langan SM et al. Clin Infect Dis 2014; 58:1497–1503. 5. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook, Australian Government Department of Health, Canberra, 2018, [Accessed February 2019]. 6. Zhang Y et al. J Stroke Cerebrovasc Dis. 2017;26(8):1807-1816. 7. Erskine N et al. PLoS One. 2017;12(7):e0181565. 8. Minassian C et al. PLoS Med. 2015;12(12):e1001919. 9. MacIntyre R et al. PLos ONE 2015; 10(4):e0125025. 10. ZOSTAVAX® Approved Product Information. 11. Department of Health. Immunise Australia Program. National Immunisation Program Schedule. Available at: [Accessed February 2019]. 12. Immunise Australia Program. Older Australians. Available at: [Accessed February 2019]. 13. Menzies R et al. Med J Aust 2017; 206 (6):238–239.

Proudly sponsored by:

Seqirus (Australia) Pty Ltd. 63 Poplar Road, Parkville, VIC 3052. ABN 66 120 398 067. Medical Information: 1800 42 865. Seqirus™ is a trademark of Seqirus UK Limited or its affiliates. Date of preparation: July 2018. SEQ/PNEU/0518/0116b



Item removed. Undo